Recent advances in cancer immunotherapy have shown unprecedented success in some advanced cancer patients, validating decades of work in understanding the molecular and cellular mechanism of antitumor immune response. However, low response rates for these types of therapies along with high probability of toxicity and high costs of treatment demand identification of prognostic, predictive, and toxicity biomarkers. Future success in immuno-oncology therapy development depends on the efficient integration, processing and analysis of a wide variety of genomic, metabolomic, proteomic and other data types, at scale and to regulatory standards.
In this webinar, Genedata data scientist, Dr. Nadezda Masloboeva-Siwach explores the challenges in immuno-oncology and outlines how Genedata Profiler address those challenges. She demonstrates: